Recent studies showed the pivotal regulation role of oncogenic EGFR on glycolysis in NSCLC, while treatment of NSCLC cells with EGFR-TKI reduces glucose-derived metabolites [7]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.